<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13112">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01686607</url>
  </required_header>
  <id_info>
    <org_study_id>9463-CL-1401</org_study_id>
    <nct_id>NCT01686607</nct_id>
  </id_info>
  <brief_title>Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents</brief_title>
  <acronym>MYCOS</acronym>
  <official_title>A Multicenter Cohort Study of the Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>World Health Information Science Consultants, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <authority>European Union: European Medicines Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter observational cohort study proposes to establish the risks of short and
      long-term outcomes in users of parenteral micafungin and in users of other parenteral
      antifungal agents from 2005 through 2012 with follow-up until 2017.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All eligible patients treated with a parenteral antifungal agent at any time during the
      years 2005-2012 in each of the participating hospitals, will be included in the study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Treatment-emergent hepatic injury or dysfunction</measure>
    <time_frame>Up to 30 days after termination of the index treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Data will be used of patients treated during the years 2005-2012 with a parenteral antifungal agent in the participating centers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-emergent renal failure or dysfunction</measure>
    <time_frame>Up to 30 days after termination of the index treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Data will be used of patients treated during the years 2005-2012 with a parenteral antifungal agent in the participating centers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rehospitalization for the parenteral treatment of fungal infections</measure>
    <time_frame>Up to 30 days after termination of the index treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Data will be used of patients treated during the years 2005-2012 with a parenteral antifungal agent in the participating centers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death from hepatocellular carcinoma (HCC)</measure>
    <time_frame>Up to 13 years after treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>On a long-term basis up to 13 years from 2005-2017.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">35000</enrollment>
  <condition>Systemic Fungal Infections</condition>
  <arm_group>
    <arm_group_label>1) parenteral micafungin users</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>2) other parenteral antifungal users</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parenteral micafungin application</intervention_name>
    <arm_group_label>1) parenteral micafungin users</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Other parenteral antifungal drugs</intervention_name>
    <arm_group_label>2) other parenteral antifungal users</arm_group_label>
    <other_name>'other antifungals' include the following drugs:</other_name>
    <other_name>caspofungin, anidulafungin, fluconazole, itraconazole, voriconazole, amphotericin B (various formulations)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with parenteral antifungals in tertiary referral centers across the
        United States.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hospitalized and treated with parenteral antifungal medication

          -  first time treatment of the patient with parenteral antifungal in the medical center
             was anytime from 2005 through 2012

        Exclusion Criteria:

          -  prior diagnosis of hepatocellular carcinoma

          -  had received parenteral antifungal therapy during the 6 months prior to index
             hospitalization
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lead Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>WHISCON, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hospital and Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Office of Research Services</name>
      <address>
        <city>Philadephia</city>
        <state>Pennsylvania</state>
        <zip>19104-6205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-2582</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 11, 2014</lastchanged_date>
  <firstreceived_date>September 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antifungals (parenteral)</keyword>
  <keyword>Micafungin</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Hepatic toxicity</keyword>
  <keyword>Renal toxicity</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Antifungal Agents</mesh_term>
    <mesh_term>Clotrimazole</mesh_term>
    <mesh_term>Miconazole</mesh_term>
    <mesh_term>Anidulafungin</mesh_term>
    <mesh_term>Micafungin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
